Advertisement FDA approves Minrad's sNDA for Sojourn Sevoflurane - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

FDA approves Minrad’s sNDA for Sojourn Sevoflurane

The FDA has approved Minrad's supplemental new drug application for the extension of the expiration date of Sojourn Sevoflurane to three years.

Sevoflurane, also called fluoromethyl hexafluoroisopropyl ether, is an inhalation anesthetic, non-flammable, highly fluorinated methyl isopropyl ether used for induction and maintenance of general anesthesia. Together with desflurane, it is reportedly replacing isoflurane and halothane in modern anesthesiology.